1 – 59 of 59
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
Brain injury markers in blood associate with generalised oedema on computed tomography after cardiac arrest
(
- Contribution to conference › Abstract
- 2020
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
- 2019
-
Mark
Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis
(
- Contribution to journal › Letter
- 2017
-
Mark
Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
(
- Contribution to journal › Article
- 2016
-
Mark
Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease
(
- Contribution to journal › Article
- 2014
-
Mark
The amyloid-β degradation pattern in plasma: A possible tool for clinical trials in Alzheimer's disease
(
- Contribution to journal › Article
- 2013
-
Mark
Serum but not Cerebrospinal Fluid levels of Insulin-Like Growth Factor-I (IGF-I) and IGF-Binding Protein-3 (IGFBP-3) are Increased in Alzheimer ́s Disease
2013) Endokrindagarna, 2013(
- Contribution to conference › Poster
- 2012
-
Mark
Age and diagnostic performance of Alzheimer disease CSF biomarkers
(
- Contribution to journal › Article
- 2011
-
Mark
Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases
(
- Contribution to journal › Article
- 2010
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2010) 23rd Congress Meeting of European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 20. p.328-329(
- Contribution to journal › Published meeting abstract
-
Mark
An enzyme activity as a potential biomarker for Alzheimer's disease.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.497-498(
- Contribution to journal › Published meeting abstract
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Convergence of chromogranin and amyloid metabolism in the brain.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.511-511(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
(
- Contribution to journal › Article
-
Mark
The PPAR-alpha gene in Alzheimer's disease: Lack of replication of earlier association
(
- Contribution to journal › Article
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2009) 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes In Diabetologia 52(Suppl 1). p.677-677(
- Contribution to journal › Published meeting abstract
-
Mark
EVOLUTION OF A beta 42 AND A beta 40 LEVELS AND A beta 42/A beta 40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
(
- Contribution to journal › Article
- 2008
-
Mark
Non-neurological surgery results in a neurochemical stress response
(
- Contribution to journal › Letter
-
Mark
Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides
(
- Contribution to journal › Article
-
Mark
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
- 2007
-
Mark
Cerebrospinal fluid protein reactions during non-neurological surgery
(
- Contribution to journal › Article
- 2006
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
- 2005
-
Mark
Increased CSF/serum albumin ratio: a recurrent finding in violent offenders.
(
- Contribution to journal › Article
-
Mark
Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
(
- Contribution to journal › Article
- 2003
-
Mark
Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
(
- Contribution to journal › Article
-
Mark
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
(
- Contribution to journal › Article
-
Mark
Increased frequency of a new polymorphism in the cycle 2 (cdc2) gene in patients with Alzheimer's disease frontotemporal dementia
(
- Contribution to journal › Article
- 2002
-
Mark
Productivity scenarios for the Asa Forest Park
2002) p.355-380(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors
(
- Contribution to journal › Article
- 2001
-
Mark
Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry
(
- Contribution to journal › Article
-
Mark
Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders
(
- Contribution to journal › Article
-
Mark
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Both total and phosphorylated tau are increased in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values
(
- Contribution to journal › Article
-
Mark
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype
(
- Contribution to journal › Article
- 2000
-
Mark
Nya rön om Alzheimers sjukdom: Gott hopp om att biokemiska markörer kan skärpa diagnostiken
(
- Contribution to journal › Article
-
Mark
Intrathecal release of nitric oxide in Alzheimer's disease and vascular dementia
(
- Contribution to journal › Article
-
Mark
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
(
- Contribution to journal › Article
-
Mark
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD
(
- Contribution to journal › Article
-
Mark
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
(
- Contribution to journal › Article
-
Mark
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma
(
- Contribution to journal › Article
-
Mark
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
(
- Contribution to journal › Article
- 1999
-
Mark
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
(
- Contribution to journal › Article
- 1998
-
Mark
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease
(
- Contribution to journal › Article